research Resistant alopecia areata treated with tofacitinib
Tofacitinib can be effective in treating hair loss caused by alopecia areata.
Search
for
Sort by
Research
150-180 / 1000+ results research PC-SPES Studies Promising, But Manufacturer Shuts Down
Promising cancer treatments were found, but the manufacturer closed.
research Radyoterapinin Metastatik Meme Kanseri Hücrelerindeki Mitokondri İlişkili Yolaklar Üzerine Etkisi
Radiotherapy affects mitochondrial-related genes in metastatic breast cancer cells.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research Tofacitinib therapy for children with severe alopecia areata
Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
research Post-tyrosinase Inhibition of Melanogenesis by Melatonin in Hair Follicles in Vitro
research ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
research A Case of Inflammatory Nonscarring Alopecia Associated With the Tyrosine Kinase Inhibitor Nilotinib
A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.
research 014 Tyrosine Kinase 2 Inhibition Ameliorates the Phenotype of Lesional Alopecia Areata Scalp Skin Ex Vivo, and Reverses the Induction of Human Alopecia Areata in a Humanized Mouse Model
TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.
research Gefitinib: an adverse effects profile
Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.
research Gefitinib-induced hair alterations: Figure 1
Gefitinib can cause slower, finer, brittle, and curly scalp hair.
research Gene detection in a family with monilethrix and treatment with 5% topical minoxidil
5% topical minoxidil improves hair density and quality in monilethrix patients.
research Efficacy of systemic minoxidil and tofacitinib combination in treatment‐resistant alopecia universalis
Using minoxidil and tofacitinib together can effectively treat severe hair loss.
research Journal of Population Therapeutics and Clinical Pharmacology
Baricitinib is more effective than methotrexate for severe alopecia areata.
research Monilethrix treated with oral retinoids
Oral etretinate improved hair length and reduced beading in monilethrix.
research Molecular pathways involved in hair follicle tumor formation: all about mammalian target of rapamycin?
mTOR may link different pathways in hair follicle tumor formation.
research AMPK Phosphorylates ZDHHC13 to Increase MC1R Activity and Suppress Melanomagenesis
AMPK activation may reduce melanoma risk in red-haired individuals.
research 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata
ITK inhibitors may effectively treat alopecia areata.
research Aberrant Activation of the Hedgehog Pathway in Cutaneous Melanoma: Therapeutic Potential of Pharmacological Inhibitors
Hedgehog pathway inhibitors could be effective in treating melanoma.
research Tofacitinib in the Recalcitrant Cases of Alopecia Areata: A Pilot Study
Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
research Efficacy of tofacitinib in pediatric alopecia universalis
Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
research Bicalutamide
research Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging
AZD6244 treatment causes skin aging effects by depleting skin stem cells.
research Matriptase: Potent Proteolysis on the Cell Surface
Matriptase is crucial for skin, hair, and immune cell health, and its imbalance can lead to cancer.
research Case Report of a Patient With Psoriasis Vulgaris, Psoriatic Arthritis and Alopecia Universalis Successfully Treated With Tofacitinib and Methotrexate
Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.
research Microphthalmic-associated transcription factor integrates melanocyte biology and melanoma progression.
Mitf plays a key role in melanoma progression and is linked to disease stage.
research Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia
Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.
research A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
Ritlecitinib was generally well tolerated in children with alopecia areata.